Suicide Risk and Antidepressants. Background 1990 Case reports 2003 Advisory: pediatric patients 2004 Warning: children and adolescents 2005 Advisory:

Slides:



Advertisements
Similar presentations
1 Eloise E. Kaizar The Ohio State University Combining Information From Randomized and Observational Data: A Simulation Study June 5, 2008 Joel Greenhouse.
Advertisements

Family Medicine Potpourri Some of the topics selected by editors of Journal Watch as top stories of 2013.
Pharmacologic Treatments. 2 Cognitive Behavioural Therapy (CBT) Psychosocial Interventions.
Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.
Depression in Children and Adolescents Graham J. Emslie, M.D. UT Southwestern Medical Center at Dallas and Children’s Medical Center.
Suicidality and Anti-epileptic Drugs: Status of Clinical Trial Data Analysis Evelyn Mentari, MD, MS Division of Neurology Products.
Preventing Youth Suicide: Does Access to Care Matter? John V. Campo, MD Nationwide Children’s Hospital Ohio State University Medical Center
1 Recent Observational Studies of Antidepressants (ADs) and Suicidal Behavior Diane K. Wysowski, Ph.D. Office of Drug Safety FDA.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Pharmacologic Treatment of Pediatric Headaches El-Chammas K, Keyes J, Thompson N,
Depression in Adolescence. Topics To Be Covered n What is depression? n Prevalence in adolescence –Gender differences –Course of depression n What causes.
Chapter 14 Depressive Disorders
Where do we go from here. DBT Rescue Medication Protocol: Use Psychotropic Medication for Following 1. Psychosis and bi-polar disorders 2. Addiction (e.g.,
Suicide Prevention Education. Why are we here? Suicide is the third leading cause of death in young people between the ages of 15 and 24. Every 16 minutes.
Behavioral Health Services for Injured or Ill workers – Collaborative Care Analysis and Recommendations January 22, 2015.
Setting the Standard for Psychiatric & Addiction Services Inpatient Treatment for Adolescents Jeanne Resendez Referral Development Manager.
1 Adolescent Mental Health: Key Data Indicators Gwendolyn J. Adam, Ph.D., L.C.S.W. Assistant Professor - Department of Pediatrics Section of Adolescent.
 Sleep  Interest  Guilt  Energy  Concentration  Appetite  Psychomotor  Suicide.
Developments in Depression
Prescription Drug Abuse & Suicide SAVING GENERATION RX: PREVENTING PRESCRIPTION DRUG ABUSE IN EAST TENNESSEE SEPTEMBER 19 TH, 2014 SAMANTHA NADLER, B.S.
Suicidality and Risks of Medications Used to Treat Mental Illness A workshop presented by the College of Psychiatric and Neurologic Pharmacists.
Pediatric Depression and Anxiety Lisa Lloyd Giles, MD Medical Director, Pediatric Behavioral Health Clinic and Consultation Service, Primary Children’s.
What FDA Failed to Disclose 1991, 2006 Vera Hassner Sharav Alliance for Human Research Protection.
Continuity Clinic Depression. Continuity Clinic Objectives.
Antidepressant. Management of psychological disorders Medical treatment Psychotherapy Support groups.
Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.
 Major depressive disorder (MDD) is a debilitating condition that has been increasingly recognized among youth  Prevalence of current or recent depression.
Treatment for Adolescents With Depression Study (TADS)
Major Depressive Episode:  loss of interest and pleasure for at least 2 weeks Manic Episode:  elevated an expansive mood for at least 1 week Mixed Episode:
Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.
Erin Dillon-Naftolin, MD September 19, 2015
Case Finding and Care in Suicide: Children, Adolescents and Adults Chapter 36.
June 11, IOM, Reducing Suicide, 2002 Statement of Task w Assess the science base w Evaluate the status of prevention w Consider strategies for studying.
1 Ethical issues in clinical trials Bernard Lo, M.D. February 10, 2010.
Use of Atypical Antipsychotic Drugs by Children and Adolescents in the United States: A Retrospective Cohort Study Lesley H. Curtis, PhD Center for Clinical.
1 Antidepressants and Suicidality in Adults: Data Overview M. Lisa Jones MD, MPH Medical Reviewer Division of Psychiatry Products Psychopharmacologic Drugs.
Adolescent Depression Treatment Mary Mills BSN, RN.
Jeffrey Jonas, MD Vice President CNS - Forest Research Institute Citalopram and Escitalopram Pediatric Safety Data.
Copyright Alcohol Medical Scholars Program 1 Comorbidity General Lecture Marc A. Schuckit, M.D. Department of Psychiatry University of California, San.
Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective.
Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence Jill A. Morris, PA-S.
Suicide under Crisis teams and in-patient care - England ENGLAND_SUICIDE ( ) © National Confidential Inquiry into Suicide and Homicide by People.
METHODS Articles used included children and adolescents ranging in age from infancy to 18 years of age who met the Diagnostic and Statistical Manual of.
1 Characteristics of Pediatric Antidepressant Trials Gregory M. Dubitsky, MD Division of Neuropharmacological Drug Products FDA.
SMOKING in ADOLESCENTS with PSYCHIATRIC or ADDICTIVE DISORDERS.
Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.
Managing Adolescent Depression in Primary Care. Copyright © The REACH Institute. All rights reserved. Hidden Slide: Time Table Total time: 60 minutes.
Copyright © The REACH Institute. All rights reserved. It is the policy of the University of Arkansas for Medical Sciences (UAMS) College of Medicine to.
Improving Medication Prescribing for Arkansas Children Through Off-label Education IMPACT Off-label Education Update on Depression and Anxiety in Children.
Long-term Efficacy Data for Psychiatric Drugs Rationale for Long-Term Treatment Earl Giller, MD, PhD Pfizer Global Research & Development Long-Term Efficacy.
Effectiveness of Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Adolescents with Depression Megan Boose, PA-S Evidence Based.
Developmental Considerations Most Common Adjustment Problems –Attachment problems or developmental delays in.
J Mann A Clinical Perspective on Safety and Efficacy of SSRIs in Depressed Children and Adolescents J. John Mann, MD President, American Foundation for.
An Analysis of Age and Gender Influences on the Relative Risk for Suicide & Psychotropic Drug Self- Poisoning AH Dawson 1, NA Buckley 2, IM Whyte 1, P.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
SUICIDE PREVENTION WEEK SEPTEMBER 7 – 13 **If you are in crisis and need help: call this toll-free number, available 24 hours a day, every day TALK.
Cognitive and behavioral endpoints as primary outcome variables in epilepsy clinical trials David W. Loring, Ph.D. Department of Neurology Emory University.
1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.
1 Regulatory Background on Antidepressants and Suicidality in Pediatric Patients Thomas Laughren, M.D. Team Leader, Psychiatric Drug Products Group Division.
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
Treating generalised anxiety disorder in primary care – an example of a treatment pathway Step 3: review and consideration of alternative treatments Step.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Use of Pattern Analysis to Predict Differential Relapse.
Pediatric Drug Development: A Regulatory Perspective Tiffany R. Farchione, M.D. Medical Officer, Division of Psychiatry Products US Food and Drug Administration.
What FDA Failed to Disclose 1991, 2006 Vera Hassner Sharav Alliance for Human Research Protection NJPIRG Law & Policy Center MAY 2006.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2010 American Medical Association. All rights reserved.
Basic Management of Juvenile Mood Disorders
Impact of the FDA Black Box Warning on Physician Antidepressant Prescribing and Practice Patterns: Opening Pandora's Suicide Box  Timothy W. Lineberry,
Widening the Options for Major Depressive Disorder
Suicide Prevention Education
Presentation transcript:

Suicide Risk and Antidepressants

Background 1990 Case reports 2003 Advisory: pediatric patients 2004 Warning: children and adolescents 2005 Advisory: suicidality in adults 2007 Current black box warning

The Warning Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. (Continues)

The Warning Anyone considering the use of [brand name here] or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. (Continues)

The Warning Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.

Defining Suicidality Suicidal ideation Preparatory act Nonfatal selfharm or attempt Death

More about the black box warning 9 antidepressants 24 short term placebo controlled trials N=4587 Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63:332.

More about the warning N=4587 Antidepressant 4% suicidality Placebo 2% suicidality No completed suicides Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006; 26:203.

What Should We Do? MonitorInform

Age Specific Effect Children and Adolescents Young Adults: YO65 or older Small increase in suicidality No detectable effect Probably protective Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry 2007; 164:1786.

Is there any difference between antidepressants? No difference in risk between classes: SSRIs, SNRIs, TCAs, MAOIs and other antidepressants. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160:790.

Effects of the Black Box Warning Decline in: rates of diagnosis of pediatric depression. treatment with SSRIs. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66:633.

Key points The FDA warning alerts about increased risk of suicidality Age specific effect: increased risk in children, adolescents and adults 18 – 25 years. No actual suicides were completed in the studies reviewed The FDA recommends monitoring during the first few weeks of treatment No difference between antidepressant classes